Evidence map›Paper›PMID 37616579›Full record

ArticleACS applied materials & interfaces2023

Fluorinated Silane-Modified Filtroporation Devices Enable Gene Knockout in Human Hematopoietic Stem and Progenitor Cells.

Isaura M Frost, Alexandra M Mendoza, Tzu-Ting Chiou, Philseok Kim, Joanna Aizenberg, Donald B Kohn, Satiro N De Oliveira, Paul S Weiss, Steven J Jonas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Isaura M FrostDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, California 90095, United States.ORCID 0000-0003-2851-1008
Alexandra M MendozaDepartment of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095, United States.
Tzu-Ting ChiouDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States.
Philseok KimJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States.ORCID 0000-0001-5814-2675
Joanna AizenbergJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States.ORCID 0000-0002-2343-8705
Donald B KohnDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California 90095, United States.
Satiro N De OliveiraDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States.ORCID 0000-0002-8181-7316
Paul S WeissDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, California 90095, United States.ORCID 0000-0001-5527-6248
Steven J JonasDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States.ORCID 0000-0002-8111-0249

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Biotechnology Training in Biomedical Sciences and EngineeringT32GM067555 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GU, ZHEN · 2005 to 2019
$2.8M
Nanoscience-Inspired Acoustofluidic Assembly Lines for Gene and Cellular TherapiesDP5OD028181 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JONAS, STEVEN JOHN · 2019 to 2023
$1.9M
NIGMS NIH HHS T32 GM008042NIGMS NIH HHS T32 GM067555NIH HHS DP5 OD028181
6 · The paper itself

Abstract

Intracellular delivery technologies that are cost-effective, non-cytotoxic, efficient, and cargo-agnostic are needed to enable the manufacturing of cell-based therapies as well as gene manipulation for research applications. Current technologies capable of delivering large cargoes, such as plasmids and CRISPR-Cas9 ribonucleoproteins (RNPs), are plagued with high costs and/or cytotoxicity and often require substantial specialized equipment and reagents, which may not be available in resource-limited settings. Here, we report an intracellular delivery technology that can be assembled from materials available in most research laboratories, thus democratizing access to intracellular delivery for researchers and clinicians in low-resource areas of the world. These filtroporation devices permeabilize cells by pulling them through the pores of a cell culture insert by the application of vacuum available in biosafety cabinets. In a format that costs less than $10 in materials per experiment, we demonstrate the delivery of fluorescently labeled dextran, expression plasmids, and RNPs for gene knockout to Jurkat cells and human CD34

Indexed as

SilanesStem CellsCell- and Tissue-Based TherapyCell Culture TechniquesGene Knockout TechniquesHumansSilanesfiltroporationgene knockoutgene therapyhematopoietic stem cellsintracellular delivery

Identifiers

PMID37616579
PMCPMC10485797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.